There is decreased risk of all-cause and CV mortality in patients with transthyretin amyloidosis with cardiomyopathy treated with vutrisiran.

Amyloidosis comprises a group of disorders that accumulate modified autologous proteins in organs, mainly the kidneys. Few studies have addressed the amyloid compartmental distribution and associated ...

Carpal tunnel syndrome was linked to wild-type transthyretin amyloidosis in new research, highlighting the importance of ...

The AI model effectively spotted all subtypes of amyloidosis in the dataset, with an area under the receiver-operating characteristic curve (AUROC) of 0.93, a sensitivity of 85% for identifying ...

In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

AstraZeneca’s CARES phase III clinical programme of anselamimab in light chain amyloidosis fails to meet primary endpoint: Cambridge, UK Thursday, July 17, 2025, 09:00 Hrs [IST] ...

Anselamimab is an anti-fibril monoclonal antibody designed to reduce or eliminate amyloid deposits by binding with targets of amino acids on misfolded amyloid fibrils.

An artificial intelligence model developed by Mayo Clinic and Ultromics accurately screens for cardiac amyloidosis using a ...

Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

The CARES clinical programme is the largest prospective investigation in cardiac AL amyloidosis to date with a total of 406 patients enrolled from 19 countries globally, including 281 patients with ...